SCHEMBL318240

SCHEMBL318240

CCN(CC)C(=O)CBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31510124 0.83 LMNA (0.39)
SCHEMBL1039434 0.83 ALDH1A1 (0.43)
SCHEMBL13844086 0.81 CA12 (0.61)
SCHEMBL14241060 0.79 ALDH1A1 (0.47)
SCHEMBL3337626 0.78 LMNA (0.64)
SCHEMBL4992699 0.78 CA12 (0.54)
SCHEMBL20200082 0.78 ALDH1A1 (0.38)
SCHEMBL2327551 0.75 LMNA (0.78)
SCHEMBL6244448 0.75
SCHEMBL139066 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 US claimed
US-20150064250-A1 Tamper-Resistant Pharmaceutical Dosage Forms ExxPharma Therapeutics LLC (US) 2015-03-05 US claimed
US-7214381-B2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ANTARES PHARMA IPL AG (CH) 2007-05-08 US claimed
US-20030199426-A1 Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ANTARES PHARMA, INC. 2003-10-23 US claimed
EP-1323431-A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels Antares Pharma IPL AG (CH) 2003-07-02 EP claimed
EP-1307232-A1 NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS Antares Pharma IPL AG (CH) 2003-05-07 EP claimed
WO-2002006826-B1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT E SCRIP INC (US) 2002-04-04 WO claimed
US-20020032581-A1 Single-patient drug trials used with accumulated database: risk of habituation OPT-E-SCRIP, INC. 2002-03-14 US claimed
WO-2002011768-A1 NOVEL COMPOSITION FOR TRANSDERMAL AND/OR TRANSMUCOSAL ADMINISTRATION OF ACTIVE COMPOUNDS THAT ENSURES ADEQUATE THERAPEUTIC LEVELS ANTARES PHARMA IPL AG (CH) 2002-02-14 WO claimed
WO-2002006826-A1 SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE OPT-E-SCRIP, INC. (US) 2002-01-24 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2026-04-30 US disclosed
EP-4593631-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME Mars, Incorporated (US) 2025-08-06 EP disclosed
CN-114890994-B Histamine receptor antagonist and preparation thereof 成都施贝康生物医药科技有限公司 2024-08-02 CN disclosed
US-20240254081-A1 CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS KARE CHEMICAL TECHNOLOGIES INC. (CA) 2024-08-01 US disclosed
US-4028093-A Meta-bis anilide derivatives and their utility as herbicides STAUFFER CHEMICAL COMPANY (US) 1977-06-07 US disclosed
US-4018813-A HERBICIDES STAUFFER CHEMICAL COMPANY (US) 1977-04-19 US disclosed
US-3941581-A Meta-bis anilide derivatives and their utility as herbicides STAUFFER CHEMICAL COMPANY (US) 1976-03-02 US disclosed
US-3937729-A META-BIS ANILIDE DERIVATIVES AND THEIR UTILITY AS HERBICIDES STAUFFER CHEMICAL COMPANY (US) 1976-02-10 US disclosed